TNGX’s vopimetostat PRMT5 inhibitor expands into lung and brain tumors
TNGX said vopimetostat, a PRMT5 inhibitor, is advancing toward approval and expanding beyond pancreatic cancer into lung cancer and glioblastoma, with additional data updates expected at ESMO.